Figure 4
Figure 4. The inhibition of Tregs augments antitumor responses in reconstituted mice. (A) Lymphodepleted mice were transferred intravenously with 40 × 106 naive spleen cells and then injected SD with MCA205 tumor cells. Next, these mice were treated with anti–CD25 mAb (PC61) to inhibit CD4+CD25+Foxp3+ Tregs. Twelve days later, the percentage of CD4+CD25+Foxp3+ Tregs in the TDLN cells were assessed by FACS analysis. Treatment with PC61 significantly reduced the percentage of CD4+CD25+Foxp3+ Tregs. (B) Reconstituted mice were inoculated subcutaneously with 1 × 105 MCA205 tumor cells. On the same day, mice were injected intraperitoneally with PC61. The combination of lymphodepletion, spleen cell transfer, and PC61 treatment significantly suppressed skin tumor growth.

The inhibition of Tregs augments antitumor responses in reconstituted mice. (A) Lymphodepleted mice were transferred intravenously with 40 × 106 naive spleen cells and then injected SD with MCA205 tumor cells. Next, these mice were treated with anti–CD25 mAb (PC61) to inhibit CD4+CD25+Foxp3+ Tregs. Twelve days later, the percentage of CD4+CD25+Foxp3+ Tregs in the TDLN cells were assessed by FACS analysis. Treatment with PC61 significantly reduced the percentage of CD4+CD25+Foxp3+ Tregs. (B) Reconstituted mice were inoculated subcutaneously with 1 × 105 MCA205 tumor cells. On the same day, mice were injected intraperitoneally with PC61. The combination of lymphodepletion, spleen cell transfer, and PC61 treatment significantly suppressed skin tumor growth.

Close Modal

or Create an Account

Close Modal
Close Modal